Thymidine Kinase 2 Deficiency (TK2d) Latest Advances
Find the Latest Research About Thymidine Kinase 2 Deficiency (TK2d)
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Management of patients with thymidine kinase 2 deficiency: where are we now?
Journal: Expert opinion on pharmacotherapy
Published: August 15, 2026
Use of nucleoside therapy for mitochondrial DNA depletion/deletion syndrome (MDDS).
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: June 23, 2026
Nucleoside therapy for thymidine kinase 2 deficiency: Long-term outcomes from a Brazilian cohort.
Journal: Journal of neuromuscular diseases
Published: May 20, 2026
Clinical development in primary mitochondrial diseases at a translational inflection point: Lessons, mechanisms, and emerging therapeutic strategies.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 21, 2026
Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?
Journal: Cell metabolism
Published: April 18, 2026
Transforming the natural course of infantile onset thymidine kinase 2 deficiency through early nucleoside replacement therapy.
Journal: Journal of neuromuscular diseases
Published: April 07, 2026
Quantitative Muscle MRI Fat Fraction as a Biomarker of Disease Severity in Mitochondrial Myopathies.
Quantitative Muscle MRI Fat Fraction as a Biomarker of Disease Severity in Mitochondrial Myopathies.
Journal: Journal of cachexia, sarcopenia and muscle
Published: February 17, 2026
Progress and perspectives in primary mitochondrial myopathy: Highlights from the 2025 mitochondrial medicine masterclass with a focus on TK2 deficiency.
Journal: Therapeutic advances in rare disease
Published: January 14, 2026
Patients' lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study.
Journal: Therapeutic advances in rare disease
Published: December 09, 2025
2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future.
Journal: Therapeutic advances in rare disease
Published: December 06, 2025
Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single-Dose Phase 1 Study.
Journal: Clinical pharmacology in drug development
Published: October 07, 2025
Last Updated: 11/08/2026